Outlook Therapeutics (OTLK) 10% owner Syntone Ventures bought 714,286 shares

Insider transactions reported

Syntone Ventures LLC (10% owner at Outlook Therapeutics Inc., OTLK) reported that they bought 714,286 shares on Apr 15, 2024. After these transactions the filing shows 1,705,438 shares held directly.

Reporting person

Syntone Ventures LLC

Options and other derivatives

Holdings before and after

• Common Stock: 991,152 to 1,705,438 direct
• Warrant (Right to Buy): 0 to 1,071,429 direct

Footnotes from the filing

1. 1. Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the SPA ), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the Issuer ) and Syntone Ventures LLC ( Syntone ), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024.
2. 2. Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the Reverse Stock Split ). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock.

Transaction codes in this filing

Open-market purchase:

Code P marks a purchase in the open market or a private deal. The insider paid for these securities.

FAQ